Glucocorticoids

ApprovedSmall molecule

Novartis

Glucocorticoids is one of 335 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Approved.

Indications

Total Trials

Active Trials

334

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymyalgia RheumaticaActive, not recruiting

Adrenal InsufficiencyActive, not recruiting

VasculitisActive, not recruiting

Kidney TransplantActive, not recruiting

FibrosisActive, not recruiting

PemphigusActive, not recruiting

Inflammatory ResponseActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

HypertensionActive, not recruiting

Giant Cell ArteritisActive, not recruiting

Polymyalgia RheumaticaPhase 3

Active, not recruiting

Adrenal InsufficiencyPreclinical

Active, not recruiting

VasculitisApproved

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

FibrosisApproved

Active, not recruiting

PemphigusPhase 1/Phase 2

Active, not recruiting

Inflammatory ResponseApproved

Active, not recruiting

Chronic RhinosinusitisApproved

Active, not recruiting

HypertensionPreclinical

Active, not recruiting

Giant Cell ArteritisPhase 1/Phase 2

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Glucocorticoids

Novartis

Approved

1 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

Platelet Rich Plasma

ZZagazig University

Preclinical

25 5

Enbrel

IImmunex

Preclinical

2 6

Catapres

Boehringer Ingelheim

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Paracetamol

GSK

Preclinical

4 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Lunesta

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Efficacy and Safety

NCT06697535

Phase 2Active, not recruiting

Idiopathic Inflammatory Myopathies

NCT05379634

Q4 2026

Phase 1/2Not yet recruiting

Pemphigus

NCT06663943

Q3 2027

Post-ApprovalRecruiting

Recurrence Free Survival

NCT06468709

Q2 2028

N/ANot yet recruiting

Pemphigus

NCT06904040

Clinical

Trials by Indication[1]

Glucocorticoid5 trials

Glucocorticoid on the Prognosis of TEVAR

Unknown status·—·N/A·NCT02523300·240 enrolled

Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO

Unknown status·SSun Yat-sen University·Phase 3·NCT04548284·142 enrolled

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Completed·—·N/A·NCT02147015·248 enrolled

Show 2 more trials

Glucocorticoid Injection in Patients With Lumbar Radicular Pain

Completed·—·Phase 4·NCT05571046·60 enrolled

Glucocorticoid Induced Whole Body Catabolisme

Completed·UUniversity of Aarhus·Phase 2·NCT01762540·19 enrolled

Allergic Bronchopulmonary Aspergillosis4 trials

Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT00974766·92 enrolled

Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01321827·100 enrolled

A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT02440009·191 enrolled

Show 1 more trial

A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT03133299·30 enrolled

Vasculitis3 trials

Low-dose Glucocorticoid Vasculitis Induction Study

Unknown status·—·Phase 4·NCT02198248·140 enrolled

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Completed·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 1/2·NCT05197842·93 enrolled

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Completed·UUniversity of Pennsylvania·Phase 3·NCT00987389·704 enrolled

Pemphigus2 trials

A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.

Not yet recruiting·CChao Ji·Phase 1/2·NCT06663943·100 enrolled

A Single-center Study of CM313 in Patients With Pemphigus

Not yet recruiting·SSichuan Provincial People's Hospital·N/A·NCT06904040·20 enrolled

Lupus Nephritis2 trials

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting·NNanjing University School of Medicine·Phase 2·NCT07340463·50 enrolled

Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis

Unknown status·XXiangya Hospital of Central South University·Phase 4·NCT05933213·205 enrolled

28 more indications

Fibrosis2 trials

A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04762810·40 enrolled

A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04762784·40 enrolled

Paroxysmal Nocturnal Hemoglobinuria2 trials

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT01760096·50 enrolled

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT01642979·120 enrolled

Giant Cell Arteritis2 trials

Bosentan in the Treatment of Giant Cell Arteritis

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06957002·40 enrolled

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 1/2·NCT03745586·18 enrolled

Efficacy and Safety2 trials

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

Recruiting·GGuangzhou JOYO Pharma Co., Ltd·Phase 2·NCT06697535·35 enrolled

Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

Recruiting·SShanghai Changzheng Hospital·Phase 4·NCT07152366·96 enrolled

Crohn's Disease1 trial

Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

Active, not recruiting·TTongji Hospital··NCT06673134·100 enrolled

Kidney Transplant1 trial

Iguratimod in Kidney Transplant Recipients

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT02839941·60 enrolled

Adrenal insufficiency1 trial

The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases

Completed·UUniversity of Leeds··NCT03575247·111,804 enrolled

ANCA-Associated Vasculitis1 trial

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

Completed·MMassachusetts General Hospital·Phase 4·NCT02169219·20 enrolled

Idiopathic Inflammatory Myopathies1 trial

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05379634·36 enrolled

Treatment1 trial

MSC for Treatment of cGVHD After Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT04692376·152 enrolled

GBM1 trial

A Study With Imlifidase in Anti-GBM Disease

Terminated·HHansa Biopharma AB·Phase 3·NCT05679401·50 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

Recruiting·SShanghai Changzheng Hospital·Phase 4·NCT07152340·64 enrolled

Inflammatory Response1 trial

Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis

Completed·FFundació Sant Joan de Déu·Phase 4·NCT02571517·94 enrolled